A hypothesis paper authored by Krishna Sriram from the University of California, San Diego proposes a pathobiological model for COVID-19 centered on an imbalance between ACE1 and ACE2 enzymes. The paper suggests therapeutic approaches to restore balance, including repurposing approved drugs like ARBs and ACEIs. The content is sourced from the paperswithcode platform.
Use Cases
- Testing drug repurposing hypotheses based on the ACE1/ACE2 imbalance model
- Analyzing molecular pathways for COVID-19 based on the proposed centrality of angiotensin signaling
- Evaluating potential decoy therapies based on the suggestion of recombinant ACE2 or ACE2 peptides
Strengths
- Proposes a specific, testable hypothesis with four concrete therapeutic approaches
- Authored by a researcher from a recognized institution, University of California, San Diego
Limitations
- Description metadata is limited; actual data quality requires manual inspection after download
- Column-level documentation is absent; field semantics must be inferred after download
Provenance
- Source
- University of California, San Diego